Till startsida
To content Read more about how we use cookies on gu.se
Start or stop image slideshow
  • Forssell-Aronsson Lab Members

  • MRI of treatment with Lu-177-octreotate

  • Oncogenic network analysis of tumor treatment response

  • Dosimetric measurements of Lu-177-octreotate

  • Transcriptional response after At-211 treatment

Forssell-Aronsson Lab

The Forssell-Aronsson Lab is situated at the Institute of Clinical Sciences, Sahlgrenska Academy, University of Gothenburg and conducts research within nuclear medicine and radiation biology. The basic science laboratory is located at the Sahlgrenska Cancer Center and the Sahlgrenska University Hospital.


The Lab is also included in the Sahlgrenska Translational Neuroendocrine Cancer Group (SATNEC)

Research Summary

Many tumour types are difficult to cure, especially metastatic disease. Therapy using radiopharmaceuticals could then be useful, due to the possibility to reach cancer cells which have spread within the body. New knowledge regarding tumour biology, pathology and molecular biology demonstrates more tumour specific features/biomarkers that can be used for development of more specific radiopharmaceuticals and treatment strategies.

Our aim is to study the possibilities to develop, optimise and apply new radiopharmaceuticals for therapy, and to optimise treatment protocols.

Some of the specific aims are:

1) To optimise treatment with radiolabelled hormone analogues for hormone receptor-expressing tumours,
2) To optimise radioiodine therapy of highly differentiated thyroid tumours e.g. regarding the stunning phenomenon
3) To define possible biomarkers for radiotoxicity in tumour and normal tissues
4) To optimise radionuclide therapy by using enhanced knowledge based on basal molecular studies of radiobiological effects on tumour tissue and critical normal tissues.
5) To enhance the knowledge on radiation dosimetry and tolerance doses for radionuclide therapy in critical normal tissues

A large part of the research is performed using the radiolabelled somatostatin analogue 177Lu-octreotate for therapy of neuroendocrine tumours expressing somatostatin receptors. We try to increase the radiobiological effects on tumour tissue by using optimal fractionation schedules, increasing the receptor expression, reducing saturation of receptors and/or combination with other agents (radiosensitising). We try to reduce the side effects on critical normal tissues, e.g. by reducing kidney uptake and kidney toxicity. We also try to find biomarkers for radiobiological effects (toxicity) on tumour and normal tissues.

Research Tools and Resources

We perform studies on cell culture, mice, rats and patients. Pharmacokinetic and dosimetric studies are performed in tumour-bearing animals and man. Studies on toxicity and biological effects (animals) utilizes e.g imaging techniques (scintigraphy, MRI), histopathology and gene expression analysis.

Current Group Members

Eva Forssell-Aronsson (ResearchGate), PhD, Professor
Britta Langen (ResearchGate), PhD, Researcher
Johan Spetz (ResearchGate), PhD, Researcher
Mikael Montelius (ResearchGate), PhD, Researcher
Emman Shubbar (ResearchGate), PhD, Researcher
Viktor Sandblom (ResearchGate), PhD-student
Ingun Ståhl, PhD-student
Malin Larsson, PhD-student
Charlotte Andersson (ResearchGate), PhD-student
Arman Romiani (ResearchGate), Research Associate
Mikael Elvborn (ResearchGate), Research Associate
Sofia Saadati, Research Associate













Principal Investigator

Eva Forssell-Aronsson
Professor/Medical Physicist

Contact Information

Dept. of Radiation Physics

Gula stråket 2B, Sahlgrenska University Hospital, 413 45, Gothenburg

Visiting Address:
Dept. of Radiation Physics, Sahlgrenska University Hospital

+46 31 7866746

Short film on the application of radiolabeled peptides for targeted therapy

Page Manager: Johan Spetz|Last update: 5/19/2017

The University of Gothenburg uses cookies to provide you with the best possible user experience. By continuing on this website, you approve of our use of cookies.  What are cookies?